Skip to main navigation

Top bar

Biogen.com Information Request Sign up for Alerts Search

Investor Relations

Overview

News

Events Presentations

SEC Filings Annual Reports

Stock Quote & Chart Analyst Coverage Investor FAQs

Governance Documents Committee Composition & Charters Leadership Code of Business Conduct Contact the Board

News

News

News Category

Year

October 30, 2019

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

October 22, 2019

Biogen Reports Q3 2019 Revenues of $3.6 Billion

October 22, 2019

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

October 21, 2019

Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week

October 2, 2019

Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

October 1, 2019

Biogen Announces Leadership Update

September 23, 2019

Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

September 18, 2019

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

September 17, 2019

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

September 13, 2019

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 11 - 20 of 705

Footer

Investors
Careers
Our Stories
Contact Us

Follow us

Bottom

Privacy Policy
Terms & Conditions
Forward-Looking Statements
Community Guidelines

Investor Relations

Overview

News

Events & Presentations

Events
Presentations

Financials

SEC Filings
Annual Reports

Stock Information

Stock Quote & Chart
Analyst Coverage
Investor FAQs

Corporate Governance

Governance Documents
Committee Composition & Charters
Leadership
Code of Business Conduct
Contact the Board

Top bar

Biogen.com

Information Request

Sign up for Alerts

Search

Follow us